Polymorphic form of sepiapterin

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11130760
SERIAL NO

16464916

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular BH4 levels or with dysfunction of various BH4 dependent metabolic pathways, which involves administering to the patient an effective amount of the crystalline form.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PTC THERAPEUTICS MP INC100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kishimoto, Kaito Narashino, JP 2 14
Komoda, Taichi Narashino, JP 3 22
Levy, Daniel E San Mateo, US 26 305
Matsumoto, Takayoshi Narashino, JP 9 36
Murata, Shunichi Narashino, JP 3 22
Shiro, Yuichi Narashino, JP 4 29
Yoshino, Hiroshi Narashino, JP 108 1156

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 28, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 28, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00